| Literature DB >> 30170925 |
Rui Yang1, Yu Chen1, Liangkun Pan1, Yanyan Yang1, Qiang Zheng1, Yue Hu2, Yuxi Wang1, Liangren Zhang1, Yang Sun2, Zhongjun Li1, Xiangbao Meng3.
Abstract
Indoleamine 2,3-dioxygenase 1 (IDO1) is regarded as a promising target for cancer immunotherapy. Many naphthoquinone derivatives have been reported as IDO1 inhibitors so far. Herein, two series of naphthoquinone derivatives, naphthoindolizine and indolizinoquinoline-5,12-dione derivatives, were synthesized and evaluated for their IDO1 inhibitory activity. Most of the target compounds showed significant inhibition potency and high selectivity for IDO1 over tryptophan 2,3-dioxygenase (TDO). The structure-activity relationship was also summarized. The most potent compounds 5c (IC50 23 nM, IDO1 enzyme), and 5b' (IC50 372 nM, HeLa cell) were identified as promising lead compounds.Entities:
Keywords: Cancer immunotherapy; Indoleamine 2,3-dioxygenase 1; Indolizinoquinoline-5,12-dione derivatives; Naphthoindolizine
Mesh:
Substances:
Year: 2018 PMID: 30170925 DOI: 10.1016/j.bmc.2018.08.028
Source DB: PubMed Journal: Bioorg Med Chem ISSN: 0968-0896 Impact factor: 3.641